What's Happening?
The VTT Technical Research Centre of Finland has filed a challenge against a patent held by The Every Co at the European Patent Office, while its spinoff, Onego Bio, sues The Every Co in the U.S. courts. The patent in question involves the production of ovalbumin, a primary protein in egg white, via precision fermentation. VTT claims that the technology for producing ovalbumin in the fungus Trichoderma reesei was public knowledge before Every's patent filing. Onego Bio is seeking to invalidate Every's U.S. patent, alleging it is 'invalid and unenforceable.'
Why It's Important?
This legal battle highlights the competitive and rapidly evolving landscape of alternative protein technologies. The outcome of this dispute could have significant implications for the industry, affecting the ability of companies to secure patents and protect their innovations. The case underscores the challenges faced by startups in navigating intellectual property rights, which are crucial for attracting investment and establishing market presence. The resolution of this dispute may influence future patent filings and collaborations in the alternative protein sector, potentially shaping the industry's growth and innovation trajectory.
What's Next?
The European Patent Office will review the challenge, and both parties will present their arguments. The outcome could lead to the revocation, amendment, or maintenance of the patent. In the U.S., the lawsuit will proceed in the Western District of Wisconsin, where Onego Bio seeks a declaratory judgment. The case may set precedents for how intellectual property disputes are handled in the alternative protein industry. Companies involved in similar technologies will likely watch the proceedings closely, as the decisions could impact their own patent strategies and competitive positioning.
